Rodríguez–Sixtos HF, Cantero VMA

Language: Spanish
References: 27
Page: 138-144
PDF size: 656.39 Kb.

ABSTRACT

Introduction: Cyclosporine A is an immunomodulator agent who suppresses the activation and proliferation of T cells and the liberation of interleukins. It has been used successfully for the treatment of ocular pathologies, which are mediated by T cells as it is the case of pterygium.
The objective was to determine if Cyclosporine A, being a modulator of the immune-inflammatory response, is an effective alternative for the treatment of the ocular symptoms related to pterygium in patients in which medical treatment is indicated.
Methods: 73 patients were randomly distributed in two groups, Methylcellulose and Cyclosporine A 0.1%. Symptoms like burning sensation, itching, foreign body sensation and photophobia were subjectively evaluated, and the reduction of pink eye objectively.
Results: Cyclosporine A was statistically superior to the Methylcellulose (P=‹0.001) for diminishing ocular symptoms and pink eye, taking in account the comparison of the average of the intensity scale of the symptoms in every visit.
Conclusions: Cyclosporine A 0.1% was safe and effective in reducing symptoms and pink eye. It was also well tolerated and didn’t produce severe adverse effects.

REFERENCES

1. Buratto L, Phillips R. L, Carito G y cols. Pterygium Surgery. SLACK , 2000.

2. Rosenthal JW. Chronology of pterygium therapy. Am J Ophthalmol 1953; 36:1016-16

3. Di Girolamo N, Kumar R.K, Coroneo MT, Wakefield D. UVD-mediated induction of interleukin-6 and 8 in pterygia and cultured human pterygium ephithelial cells. Invest Ophthalmol Vis Sci 2002; 43(11):3430-7.

4. Dushku N, Reid TW. Immunohistochemical evidence that human pterygia originate from an invasion of vimentinexpressing altered limbar ephithelial basal cells. Curr Eye Res 1994; 13:473-81.

5. Hect Fondazione, Shoptaugh MG. Winglets of the eye: dominant transmission of early adult pterygium of the conjunctiva. J Med Genet 1990; 27(6):392-4.

6. Ishioka M, Shimmura S, Yagi Y, Tsubota K. Pterygium and dry eye. Ophthalmologica 2001; 215:209-211.

7. Tsironi S, Ioachim E, Machera M, Aspiotis M, Agnatis N, Psillas K. Immunohistochemical HLA-DR antigen expression with lymphocyte subsets and proliferative activity in pterygium. In Vivo 2002 ; 16(5):299-306.

8. Ioachim-Velogianni E, Tsiori E, Agnantis N y cols. HLA-DR antigen expression in pterygium epithelial cells and lymphocyte subpopulations: an immunohistochemistry study. Ger J Ophthalmol 1995; 4(2):123-9.

9. Perra MT, Maxia C, Zucca I, Piras F, Sirigu P. Immunohistochemical study human pterygium. Histol Histopathol 2002; 17(1):139-49.

10. Kria L, Ohira A, Amemiya T. Immunohistochemical localization of basic fibroblast grow factor, platelet derived grow factor, transforming growth factor-β and tumor necrosis factor-α in the pterygium. Acta Histochem 1996; 98:195-201.

11. Kria L, Ohira A, Amemiya T. Growth factors in cultured pterygium fibroblast: immunohistochemical and ELISA analysis. Graefes Arch Clin Exp Ophthalmol 1998; 236:702-708.

12. Pinkerton O, Hokama Y, Shigemura L. Immunologic basis for the phatogenesis of pterygium. Am J Ophthalmol 1984; 98(2):225-228.

13. Di Girolamo N, McCluskey P, Lloyd A, Coroneo MT, Wakefield D. Expression of MMPs and TIMPs in human pterygia and cultured pterygium epithelial cells Invest Ophthlamol Vsi Sci 2000; 41:671-679.

14. Liu YP, Schultz GS, Ren XO y cols. MMP-2 and MMP-9 levels in pterygia and matched superior conjunctiva by gelatin zymography. Invest Ophthlamol Vsi Sci 1998; 39(40):S756.

15. Di Girolamo N, Wakefield D, Coroneo MT. Differential expression of matrix metalloproteinasses and their tissue inhibitors at the advancing pterygium head. Invest Ophthlamol Vsi Sci 2000; 41(13):4142-4150.

16. Wu H, Cheng G. Cyclosporine A and Thiotepa in prevention of postoperative recurrence of pterygium. Yan Ke Xue Bao 1999; 15(2):91-2.

17. Power JW, Mullaney P, Farrel M, Collum LM. Effect of topical cyclosporine A on conjunctival T cells in patients with secondary Sjögren syndrome. Cornea 1993; 12(6):507-511.

18. Holland EJ, Chi-Chao C, Kuwabara T y cols. Immunohistologic findings and results of treatment with cyclosporine in ligneous conjunctivitis. Am J Ophthlamol 1989; 107:160-166.

19. Jing-Cheng Z, Xiu-ying J. Immunological analysis and treatment of Mooren’s ulcer with cyclosporine A applied topically. Cornea; 12(6):481-488.

20. Belin WM, Bouchard C, Frantz S y cols. Topical cyclosporine in high-risk corneal transplants. Ophthlamology 1989; 96(8):1144-1150.

21. El-Asrar AMA, Tabbara KF, Geboes K, Missotten L, Desmet V. An immunohistochemical study of topical cyclosporine in vernal keratoconjunctivitis. Am J Ophthalmol 1996; 121:156-161.

22. Hingorani M, Calder V, Buckley R y cols. The immunomodulatory effect of topical Cyclosporine A in atopic keratoconjunctivitis. Invest Ophthlamol Vsi Sci 1999; 40(2):392-399.

23. Stevenson D, Tauber J, Reis B.L y cols. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate to severe dry eye disease. A dose ranging, randomized trial. Ophthalmology 2000; 107(5):967-974.

24. Sall K, Stevenson OD, Mundorf TK, Reis BL, CsA Phase 3 Study Group. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease1. Ophthalmology 2000; 107(4):631-639.

25. Schhiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. . Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol 2000; 118:615-621.

26. Schein OD, Tielsch JM, Muñoz B, Bandeen-Roche K, West S. Relation between sign and symptoms of dry eye in the elderly. A population based perspective. Ophthalmology 1997; 104:1395-1401.

27. Begley CG, Caffery B. Use of the Dry Eye Questionnaire to measure symptoms of ocular irritation in patients with aqueous tear deficient dry eye. Cornea 2002; 21(7) 664-670.